Fortrea Holdings (FTRE) Current Deferred Revenue (2022 - 2026)
Fortrea Holdings (FTRE) reported Current Deferred Revenue of $481.3 million for Q1 2026, up 15943.33% on a YoY basis from N/an in Q1 2025, and up 1.58% quarter-over-quarter from $473.8 million in Q4 2025.
Fortrea Holdings (FTRE) Current Deferred Revenue (2022 - 2026) Analysis & Trends
Fortrea Holdings has reported Current Deferred Revenue for 5 years, with the latest figure at $481.3 million in Q1 2026.
- For the quarter ending Q1 2026, Current Deferred Revenue rose 15943.33% year-over-year to $481.3 million; the trailing twelve-month figure through Mar 2026 stood at $481.3 million (up 15943.33% YoY), and the FY2025 full-year result was $473.8 million, up 34.11% from the prior year.
- Current Deferred Revenue for Q1 2026 stood at $481.3 million, up from $473.8 million in the prior quarter.
- The five-year high for Current Deferred Revenue was $481.3 million in Q1 2026, with the low at $3.0 million in Q1 2025.
- Historically, Current Deferred Revenue has averaged $302.0 million across 5 years, with a median of $271.5 million in 2022.
- Annual changes were most pronounced in 2025 — Current Deferred Revenue slumped 98.73% — and 2026, when it jumped 15943.33%.
- Fortrea Holdings' Current Deferred Revenue stood at $271.5 million in 2022, then slipped by 21.1% to $214.2 million in 2023, then surged by 64.94% to $353.3 million in 2024, then surged by 34.11% to $473.8 million in 2025, then advanced by 1.58% to $481.3 million in 2026.
- The last three Current Deferred Revenue figures came in at $481.3 million (Q1 2026), $473.8 million (Q4 2025), and $411.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Fortrea Holdings | 1.43 Bn | 1.28 Bn | 123.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 481.30 Mn |
| Dec 31, 2025 | 473.80 Mn |
| Sep 30, 2025 | 411.60 Mn |
| Jun 30, 2025 | 381.70 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | 353.30 Mn |
| Sep 30, 2024 | 321.10 Mn |
| Jun 30, 2024 | 248.00 Mn |
| Mar 31, 2024 | 236.90 Mn |
| Dec 31, 2023 | 214.20 Mn |
| Sep 30, 2023 | 264.80 Mn |
| Jun 30, 2023 | 264.30 Mn |
| Dec 31, 2022 | 271.50 Mn |